{"id":1058,"date":"2018-06-21T08:09:10","date_gmt":"2018-06-21T06:09:10","guid":{"rendered":"https:\/\/www.ggkmedia.com\/?p=1058"},"modified":"2020-03-30T21:06:04","modified_gmt":"2020-03-30T19:06:04","slug":"klinisk-provning-av-inofer-har-godkants-av-lakemedelsverket","status":"publish","type":"post","link":"https:\/\/www.drugsson.com\/sv\/klinisk-provning-av-inofer-har-godkants-av-lakemedelsverket\/","title":{"rendered":"Klinisk pr\u00f6vning av Inofer har godk\u00e4nts av L\u00e4kemedelsverket"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-background-repeat:repeat;--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:90px;--awb-padding-bottom:90px;--awb-background-color:#eaf7ff;--awb-border-sizes-top:0px;--awb-border-sizes-bottom:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-first\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_2_3 2_3 fusion-two-third\" style=\"--awb-padding-top:50px;--awb-padding-right:50px;--awb-padding-bottom:30px;--awb-padding-left:50px;--awb-bg-color:#ffffff;--awb-bg-color-hover:#ffffff;--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% + 4% ) * 0.66666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-text fusion-text-1\"><h3>Klinisk pr\u00f6vning av Inofer har godk\u00e4nts av L\u00e4kemedelsverket<\/h3>\n<\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-last\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-first\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_2_3 2_3 fusion-two-third\" style=\"--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% + 4% ) * 0.66666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-last\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-first\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_2_3 2_3 fusion-two-third\" style=\"--awb-padding-top:50px;--awb-padding-right:50px;--awb-padding-bottom:50px;--awb-padding-left:50px;--awb-bg-color:#ffffff;--awb-bg-color-hover:#ffffff;--awb-bg-size:cover;--awb-border-color:#25afb4;--awb-border-bottom:8px;--awb-border-style:solid;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% + 4% ) * 0.66666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-text fusion-text-2\"><p>Som tidigare meddelats har Double Bond Pharmas dotterbolag Drugsson AB f\u00f6rv\u00e4rvat r\u00e4ttigheterna till Inofer (ferrosuccinat) j\u00e4rntabletter i Sverige. Trots att Inofer har funnits p\u00e5 den franska marknaden i 20 \u00e5r beh\u00f6ver produkten ett separat godk\u00e4nnande av L\u00e4kemedelsverket f\u00f6r att kunna tillhandah\u00e5llas i Sverige.<\/p>\n<p>L\u00e4kemedelsverket och forskningsetikn\u00e4mnden har den 20e juni godk\u00e4nt en svensk klinisk pr\u00f6vning av Inofer-tabletter som ska genomf\u00f6ras vid Skellefte\u00e5 lasarett och ledas av \u00f6verl\u00e4kare Kurt Boman, senior professor vid Ume\u00e5 universitet. Patientgruppen \u00e4r vuxna och \u00e4ldre med samtidig hj\u00e4rtsvikt och j\u00e4rnbrist. M\u00e5ls\u00e4ttningen \u00e4r att studera upptaget av ferrosuccinat under minst 3 m\u00e5naders behandling av patienterna med hypotesen att ferrosuccinat ska ge en \u00f6kning av j\u00e4rnniv\u00e5erna i blodet med i medeltal 25 mikrogram\/liter. Studien startar i augusti 2018 m.h.a en extern sponsor.<\/p>\n<p>\u201dVi hoppas att Inofer visar sig ge en f\u00f6rv\u00e4ntad \u00f6kning av j\u00e4rnniv\u00e5erna hos hj\u00e4rtsviktspatienterna i den kommande kliniska studien\u201d kommenterar Igor Lokot, VD f\u00f6r Double Bond Pharma och Drugsson Pharma.<\/p>\n<p><strong>Mer om j\u00e4rnbrist och hj\u00e4rtsvikt:<\/strong><\/p>\n<p>Omkring 15 % av v\u00e4rldens befolkning lider av j\u00e4rnbrist. Cirka 250\u00a0000 personer i Sverige har symptomgivande hj\u00e4rtsvikt och h\u00e4lften av dessa har samtidig j\u00e4rnbrist. Denna kombination av diagnoser leder till \u00f6kade symtom och ofta till sjukhusinl\u00e4ggningar. Behandling med vanliga j\u00e4rntabletter fungerar inte p\u00e5 grund av otillr\u00e4ckligt upptag fr\u00e5n tarmen. F\u00f6r att behandla j\u00e4rnbrist hos hj\u00e4rtsviktpatienter m\u00e5ste d\u00e4rf\u00f6r i dagsl\u00e4get j\u00e4rninneh\u00e5llande l\u00e4kemedel injiceras intraven\u00f6st p\u00e5 en v\u00e5rdinr\u00e4ttning, vilket \u00e4r resurskr\u00e4vande. Om det visar sig att ferrosuccinat-tabletter kan behandla j\u00e4rnbrist hos hj\u00e4rtsviktpatienter skulle det inneb\u00e4ra en betydande vinst f\u00f6r patienterna och f\u00f6r sjukv\u00e5rden eftersom behandlingen i s\u00e5 fall kan genomf\u00f6ras i hemmet.<\/p>\n<\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;margin-top:40px;width:100%;\"><\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-text fusion-text-3\"><h4>Nyhetsk\u00e4lla<\/h4>\n<\/div><div class=\"fusion-text fusion-text-4\"><p><a href=\"https:\/\/www.spotlightstockmarket.com\/sv\/market-overview\/nyheter\/nyhets-artikel\/?id=45454&amp;publisher=370\" target=\"_blank\" rel=\"noopener noreferrer\">Spotlight<\/a><\/p>\n<\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;margin-top:40px;width:100%;\"><\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-sharing-box fusion-sharing-box-1 boxed-icons has-taglines layout-floated layout-medium-floated layout-small-floated\" style=\"background-color:#f6f6f6;--awb-layout:row;--awb-alignment-small:space-between;\" data-title=\"Klinisk pr\u00f6vning av Inofer har godk\u00e4nts av L\u00e4kemedelsverket\" data-description=\"Klinisk pr\u00f6vning av Inofer har godk\u00e4nts av L\u00e4kemedelsverket    Som tidigare meddelats har Double Bond Pharmas dotterbolag Drugsson AB f\u00f6rv\u00e4rvat r\u00e4ttigheterna till Inofer (ferrosuccinat) j\u00e4rntabletter i Sverige. Trots att Inofer har funnits p\u00e5 den franska marknaden i 20 \u00e5r beh\u00f6ver produkten ett separat godk\u00e4nnande av L\u00e4kemedelsverket f\u00f6r att kunna\" data-link=\"https:\/\/www.drugsson.com\/sv\/klinisk-provning-av-inofer-har-godkants-av-lakemedelsverket\/\"><h4 class=\"tagline\" style=\"color:#4c5166;\">Dela inl\u00e4gget<\/h4><div class=\"fusion-social-networks sharingbox-shortcode-icon-wrapper sharingbox-shortcode-icon-wrapper-1 boxed-icons\"><span><a href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.drugsson.com%2Fsv%2Fklinisk-provning-av-inofer-har-godkants-av-lakemedelsverket%2F&amp;t=Klinisk%20pr%C3%B6vning%20av%20Inofer%20har%20godk%C3%A4nts%20av%20L%C3%A4kemedelsverket\" target=\"_blank\" rel=\"noreferrer\" title=\"Facebook\" aria-label=\"Facebook\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"Facebook\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-facebook awb-icon-facebook\" style=\"color:#ffffff;background-color:#3b5998;border-color:#3b5998;border-radius:0px;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/x.com\/intent\/post?text=Klinisk%20pr%C3%B6vning%20av%20Inofer%20har%20godk%C3%A4nts%20av%20L%C3%A4kemedelsverket&amp;url=https%3A%2F%2Fwww.drugsson.com%2Fsv%2Fklinisk-provning-av-inofer-har-godkants-av-lakemedelsverket%2F\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"X\" aria-label=\"X\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"X\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-twitter awb-icon-twitter\" style=\"color:#ffffff;background-color:#000000;border-color:#000000;border-radius:0px;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/www.linkedin.com\/shareArticle?mini=true&amp;url=https%3A%2F%2Fwww.drugsson.com%2Fsv%2Fklinisk-provning-av-inofer-har-godkants-av-lakemedelsverket%2F&amp;title=Klinisk%20pr%C3%B6vning%20av%20Inofer%20har%20godk%C3%A4nts%20av%20L%C3%A4kemedelsverket&amp;summary=Klinisk%20pr%C3%B6vning%20av%20Inofer%20har%20godk%C3%A4nts%20av%20L%C3%A4kemedelsverket%20%20%20%20%20%20%20%0D%0A%0D%0ASom%20tidigare%20meddelats%20har%20Double%20Bond%20Pharmas%20dotterbolag%20Drugsson%20AB%20f%C3%B6rv%C3%A4rvat%20r%C3%A4ttigheterna%20till%20Inofer%20%28ferrosuccinat%29%20j%C3%A4rntabletter%20i%20Sverige.%20Trots%20att%20Inofer%20har%20funnits%20p%C3%A5%20den%20franska%20marknaden%20i%2020%20%C3%A5r%20beh%C3%B6ver%20produkten%20ett%20separat%20godk%C3%A4nnande%20av%20L%C3%A4kemedelsverket%20f%C3%B6r%20att%20kunna\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"LinkedIn\" aria-label=\"LinkedIn\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"LinkedIn\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-linkedin awb-icon-linkedin\" style=\"color:#ffffff;background-color:#0077b5;border-color:#0077b5;border-radius:0px;\" aria-hidden=\"true\"><\/i><\/a><\/span><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-last\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19,4],"tags":[],"_links":{"self":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts\/1058"}],"collection":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/comments?post=1058"}],"version-history":[{"count":3,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts\/1058\/revisions"}],"predecessor-version":[{"id":1385,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts\/1058\/revisions\/1385"}],"wp:attachment":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/media?parent=1058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/categories?post=1058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/tags?post=1058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}